HPRA - Information Update on Medicines from HPRA


The 98th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

  • Adverse reaction reporting during the COVID-19 pandemic – reminder
  • Picato (ingenol mebutate) – EMA review concludes negative benefit risk balance due to risk of skin malignancy
  • Levetiracetam – risk of abnormal and aggressive behaviours
  • Cyproterone acetate – restrictions in use due to risk of meningioma
  • Carbimazole and propylthiouracil – use in pregnancy and in women of childbearing potential
  • Carbimazole – risk of acute pancreatitis
  • Testosterone-containing medicinal products: caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE)
Rate: 12345 (10) | Facebook Twitter LinkedIn Digg Yammer
In this issue
A note from Sheila McClelland, CEO NMBI to all Registrants
Naming of New Online System – Please Give us Your Opinion
HPRA - Information Update on Medicines from HPRA
June Spotlight – Maura O’Sullivan, Director of Nursing at St Gobnait's Nursing Home, Limerick
Update DetailsSend to a friendArchive